Corcept Therapeutics INC 10-Q quarterly reports

Corcept Therapeutics reports strong revenue growth driven by Hypercortisolism Products and Lifyorli, while navigating regulatory reviews and ongoing litigation.

Corcept Therapeutics reported increased product revenue for Q3 and the nine months ended September 30, 2025, driven by higher sales volume, but net income declined due to significantly increased operating expenses and R&D investments.

Corcept Therapeutics reported increased product revenue driven by higher sales volume but experienced a decline in net income due to significantly higher operating expenses, while advancing key drug candidates with positive clinical trial results and new FDA submissions.

Corcept Therapeutics' Q1 2025 revenue increased, driven by higher sales volume, while the FDA accepted the NDA for relacorilant, a potential treatment for hypercortisolism.

Corcept Therapeutics reported a significant increase in product revenue for the third quarter of 2024, alongside updates on its clinical development programs.

Corcept Therapeutics reports a significant increase in second-quarter revenue, driven by higher sales volumes and a price increase, while also advancing its clinical programs.

Corcept Therapeutics reported a significant increase in product revenue for the first quarter of 2024, alongside updates on its clinical programs and financial activities.